Back to All Events

Masterclass: Biotech Dealmaking and IP Licensing


  • Toronto, Ontario, Canada (map)

Masterclass:

Biotech Dealmaking and IP Licensing

The OBIO® Biotech Dealmaking and IP Licensing Masterclass, delivered in collaboration with BioLabs – University of Toronto and Novateur Ventures, is an intensive, hands-on training program designed to help early-stage biotech teams strategically position their pre-clinical assets for pharma partnerships and non-dilutive licensing deals.

Over 2.5 days, participants will gain practical insights into deal structures, asset valuation, AI-driven diligence, and the impact of Most Favoured Nation (MFN) pricing. The program will culminate in a live mock negotiation, giving participants an opportunity to put what they have learned into practice with seasoned pharma dealmakers.

Who Should Attend

This Masterclass is designed for early-stage and pre-clinical biotech team members who are leading partnering conversations without the support of a large corporate BD department:

» Founders, CEOs, and CSOs preparing for their first strategic alliance or licensing deal

» Senior R&D and operational biotech leaders building data rooms or supporting pharma due diligence

» Emerging biotech BD leads looking to benchmark their valuation and negotiation strategy

What Makes This Masterclass Different

» Learn directly from a global pharma BD executives, life science investors and IP counsel.

» Get practical, small-group coaching and feedback on your asset strategy.

» Participate in a case study and live negotiation, working in small teams to value a pre-clinical/IND-stage asset and negotiate a term sheet in real time.

Pricing (2.5 day masterclass): $1,600+HST

Including breakfast & lunch during the course and
private networking opportunity with pharma guest speakers.

Previous
Previous
December 3

Frontline Founders: Defence Innovation & Networking Exchange

Next
Next
February 2

2027 OBIO® Investment Summit